Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/imt-2020-0235 http://scihub22266oqcxt.onion/10.2217/imt-2020-0235 33397150!7784786!33397150     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunotherapy 2021 ; 13 (4): 289-295 Nephropedia Template TP {{tp|p=33397150|t=2021. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases |pdf=|usr=}}{{33397150}} gab.com Text An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases JO: Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33397150 #FOAvip In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-gamma, IL-6 and TNF-alpha. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality. Twit Text FOAVip An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases ????Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33397150 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33397150 #FOAvip English Wikipedia <ref>{{Cite pmid|33397150}}</ref> An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases #MMPMID33397150 Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sanchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Ane-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A Immunotherapy 2021[Mar]; 13 (4): 289-295 PMID33397150show ga In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-gamma, IL-6 and TNF-alpha. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality. |*COVID-19 Drug Treatment[MESH] |Aged, 80 and over[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antigens, CD/*immunology[MESH] |Antigens, Differentiation, T-Lymphocyte/*immunology[MESH] |Biomarkers/blood[MESH] |COVID-19/pathology[MESH] |Critical Illness[MESH] |Cytokine Release Syndrome/*drug therapy/pathology[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2[MESH]An anti-CD6 antibody for the treatment of COVID-19 patients with cytok(epmc).pdf DeepDyve Pubget Overpricing